Administering xCT inhibitors based on circadian clock improves antitumor effects

Cancer Research

Volumn 77, Issue 23, 2017, Pages 6603-6613

  Okazaki, Fumiyasu ^a   Matsunaga, Naoya ^b   Hamamura, Kengo ^c   Suzuki, Kayoko ^a   Nakao, Takaharu ^b   Okazaki, Hiroyuki ^c   Kutsukake, Masahiko ^a   Fukumori, Shiro ^a   Tsuji, Yasuhiro ^a   To, Hideto ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CYSTINE TRANSPORTER XCT; GLUTATHIONE; PROTEIN INHIBITOR; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARNTL PROTEIN, MOUSE; OXALIPLATIN; PLATINUM COMPLEX; SLC7A11 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CIRCADIAN RHYTHM; CLOCK GENE; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHRONOPHARMACOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ANTINEOPLASTIC AGENTS; ARNTL TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCADIAN CLOCKS; DRUG CHRONOTHERAPY; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; ORGANOPLATINUM COMPOUNDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFASALAZINE; TRANSCRIPTION, GENETIC;

EID: 85037704971     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-0720     Document Type: Article

References (43)

1. Stephan FK, Zucker I. Circadian rhythms in drinking behavior and loco-motor activity of rats are eliminated by hypothalamic lesions. Proc Nat Acad Sci U S A 1972;69:1583–6.
2. Alvarez JD, Sehgal A. Circadian rhythms: finer clock control. Nature 2002;419:798–9.
3. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999;98:193–205.
4. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science (New York, NY) 1998;280:1564–9.
5. Michael AK, Harvey SL, Sammons PJ, Anderson AP, Kopalle HM, Banham AH, et al. Cancer/testis antigen PASD1 silences the circadian clock. Mol Cell 2015;58:743–54.
6. Panda S, Hogenesch JB, Kay SA. Circadian rhythms from flies to human. Nature 2002;417:329–35.
7. Young MW, Kay SA. Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2001;2:702–15.
8. Dallmann R, Okyar A, Levi F. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends Mol Med 2016;22:430–45.
9. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci 2013;119:221–82.
10. Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett 2014;342:9–18.
11. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 2013;18:522–55.
12. Kato S, Negishi K, Mawatari K, Kuo CH. A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 1992;48:903–14.
13. Tew KD.Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313–20.
14. Zhang Y, Martin SG. Redox proteins and radiotherapy. Clin Oncol 2014;26:289–300.
15. Dusre L, Mimnaugh EG, Myers CE, Sinha BK. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 1989;49:511–5.
16. Chen G, Waxman DJ. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem Pharmacol 1994;47:1079–87.
17. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005;65:7446–54.
18. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013;73:1855–66.
19. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387–400.
20. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013;24:450–65.
21. Seishima R, Okabayashi K, Nagano O, Hasegawa H, Tsuruta M, Shimoda M, et al. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(þ) cancer stem cells in ulcerative colitis-related cancer. Clin Res Hepatol Gastroenterol 2016;40:487–93.
22. Okazaki F, Matsunaga N, Okazaki H, Azuma H, Hamamura K, Tsuruta A, et al. Circadian clock in a mouse colon tumor regulates intracellular iron levels to promote tumor progression. J Biol Chem 2016;291:7017–28.
23. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001;15:1633–40.
24. Gout PW, Simms CR, Robertson MC. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 2003;14:21–9.
25. Orian-Rousseau V, Ponta H. Perspectives of CD44 targeting therapies. Arch Toxicol 2015;89:3–14.
26. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013;32:5191–8.
27. Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal 2014;26:2234–9.
28. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998;93:929–37.
29. Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 2004;119:693–705.
30. Casey T, Crodian J, Suarez-Trujillo A, Erickson E, Weldon B, Crow K, et al. CLOCK regulates mammary epithelial cell growth and differentiation. Am J Physiol Regul Integr Comp Physiol 2016;311:R1125–r34.
31. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009;28:599–609.
32. Lall MM, Ferrell J, Nagar S, Fleisher LN, McGahan MC. Iron regulates L-cystine uptake and glutathione levels in lens epithelial and retinal pigment epithelial cells by its effect on cytosolic aconitase. Invest Ophthalmol Visual Sci 2008;49:310–9.
33. Okazaki F, Matsunaga N, Okazaki H, Utoguchi N, Suzuki R, Maruyama K, et al. Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. Cancer Res 2010; 70:6238–46.
34. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 2006;3:55–61.
35. Hamdan AM, Koyanagi S, Wada E, Kusunose N, Murakami Y, Matsunaga N, et al. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem 2012;287:17224–31.
36. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979;48:133–58.
37. Benhar M, Shytaj IL, Stamler JS, Savarino A. Dual targeting of the thior-edoxin and glutathione systems in cancer and HIV. J Clin Invest 2016; 126:1630–9.
38. Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. NADþ kinase as a therapeutic target in cancer. Clin Cancer Res 2016;22:5189–95.
39. Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol 2014;7:30.
40. Rutter J, Reick M, Wu LC, McKnight SL. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science (New York, NY) 2001;293:510–4.
41. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NADþ salvage pathway by CLOCK-SIRT1. Science (New York, NY) 2009;324:654–7.
42. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, et al. Circadian clock feedback cycle through NAMPT-mediated NADþ biosynthesis. Science (New York, NY) 2009;324:651–4.
43. O'Neill JS, Reddy AB. Circadian clocks in human red blood cells. Nature 2011;469:498–503.